Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73600909" target="_blank" >RIV/61989592:15110/19:73600909 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/19:00078373

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690532/pdf/pone.0220377.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690532/pdf/pone.0220377.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0220377" target="_blank" >10.1371/journal.pone.0220377</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome

Popis výsledku v původním jazyce

Troxerutin (TRX) has a beneficial effect on blood viscosity and platelet aggregation, and is currently used for the treatment of chronic varicosity. Recently, TRX can improve lipid abnormalities, glucose intolerance and oxidative stress in high-fat diet-induced metabolic disorders. In this study, we tested the effect of TRX on metabolic syndrome-associated disorders using a non-obese model of metabolic syndrome–the Hereditary Hypertriglyceridaemic rats (HHTg). Adult male HHTg rats were fed standard diet without or with TRX (150 mg/kg bwt/day for 4 weeks). Compared to untreated rats, TRX supplementation in HHTg rats decreased serum glucose (p&lt;0.05) and insulin (p&lt;0.05). Although blood lipids were not affected, TRX decreased hepatic cholesterol concentrations (p&lt;0.01) and reduced gene expression of HMGCR, SREBP2 and SCD1 (p&lt;0.01), involved in cholesterol synthesis and lipid homeostasis. TRXtreated rats exhibited decreased lipoperoxidation and increased activity of antioxidant enzymes SOD and GPx (p&lt;0.05) in the liver. In addition, TRX supplementation increased insulin sensitivity in muscles and epididymal adipose tissue (p&lt;0.05). Elevated serum adiponectin (p&lt;0.05) and decreased muscle triglyceride (p&lt;0.05) helped improve insulin sensitivity. Among the beneficial effects of TRX were changes to cytochrome P450 family enzymes. Hepatic gene expression of CYP4A1, CYP4A3 and CYP5A1 (p&lt;0.01) decreased, while there was a marked elevation in gene expression of CYP1A1 (p&lt;0.01).

Název v anglickém jazyce

Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome

Popis výsledku anglicky

Troxerutin (TRX) has a beneficial effect on blood viscosity and platelet aggregation, and is currently used for the treatment of chronic varicosity. Recently, TRX can improve lipid abnormalities, glucose intolerance and oxidative stress in high-fat diet-induced metabolic disorders. In this study, we tested the effect of TRX on metabolic syndrome-associated disorders using a non-obese model of metabolic syndrome–the Hereditary Hypertriglyceridaemic rats (HHTg). Adult male HHTg rats were fed standard diet without or with TRX (150 mg/kg bwt/day for 4 weeks). Compared to untreated rats, TRX supplementation in HHTg rats decreased serum glucose (p&lt;0.05) and insulin (p&lt;0.05). Although blood lipids were not affected, TRX decreased hepatic cholesterol concentrations (p&lt;0.01) and reduced gene expression of HMGCR, SREBP2 and SCD1 (p&lt;0.01), involved in cholesterol synthesis and lipid homeostasis. TRXtreated rats exhibited decreased lipoperoxidation and increased activity of antioxidant enzymes SOD and GPx (p&lt;0.05) in the liver. In addition, TRX supplementation increased insulin sensitivity in muscles and epididymal adipose tissue (p&lt;0.05). Elevated serum adiponectin (p&lt;0.05) and decreased muscle triglyceride (p&lt;0.05) helped improve insulin sensitivity. Among the beneficial effects of TRX were changes to cytochrome P450 family enzymes. Hepatic gene expression of CYP4A1, CYP4A3 and CYP5A1 (p&lt;0.01) decreased, while there was a marked elevation in gene expression of CYP1A1 (p&lt;0.01).

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

<a href="/cs/project/GA17-08888S" target="_blank" >GA17-08888S: Vliv silymarinu v kombinaci s hypolipidemiky na mechanismy vedoucí k akumulaci lipidů, oxidativnímu stresu a zánětu u metabolického syndromu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS One

ISSN

1932-6203

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

1-12

Kód UT WoS článku

000485006800012

EID výsledku v databázi Scopus

2-s2.0-85070703834